Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease-Reference-Cited by-同舟云学术

Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease

Published:2022-07 Issue:3 Volume:70 Page:103343
ISSN:2452-3186
Container-title:Current Research in Translational Medicine
language:en
Short-container-title:Current Research in Translational Medicine

Author:

Ali Faraat,Ilyas Anam

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference99 articles.

1. REZUROCK (belumosudil) tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson;Crye;mckesson.com,2021

2. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study;Cutler;Blood,2021

3. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease;Jagasia;J. Clin. Oncol.,2021

4. U.S. FDA Grants Full Approval of REZUROCK™ (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD);Cavaleri;Kadmon Holdings, Inc.,2021

5. FDA approves belumosudil for chronic graft-versus-host disease;FDA.GOV,2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the rationale and conducting a comprehensive assessment of KD025 (Belumosudil) as a candidate drug for inhibiting adipogenic differentiation—a systematic review;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-11-15

2. Hepatic graft-versus-host disease: what we know, when to biopsy, and how to diagnose;Human Pathology;2023-11

3. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis;Expert Review of Clinical Immunology;2023-06-29

4. An update on current and emerging drug treatments for idiopathic pulmonary fibrosis;Expert Opinion on Pharmacotherapy;2023-05-17

5. Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging;Biomedical Optics Express;2023-05-16